Achievement of Multiple Milestones in Evotec's Drug Discovery Alliances
December 18 2014 - 10:36AM
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) disclosed
today that it achieved multiple milestones in ongoing alliances
with its strategic research partners. The milestones were reached
in its multi-target collaboration with Bayer HealthCare ("Bayer")
in endometriosis and within its partnership with Janssen
Pharmaceuticals, Inc. ("Janssen") for the EVT100 series for the
treatment of CNS diseases. These milestones trigger revenues of
approx. € 8 m in total which will be recognised in the financial
year 2014.
Multi-target collaboration with Bayer
In its multi-target collaboration with Bayer, Evotec has reached
important milestones for the transition of certain molecules into
pre-clinical development for the treatment of endometriosis. These
milestones were achieved under the agreement between Evotec and
Bayer signed in October 2012. The goal of this collaboration is to
identify three clinical candidates within the five-year alliance.
Both parties contribute innovative drug targets and high-quality
technology infrastructures and share the responsibility for early
research and pre-clinical characterisation of potential clinical
candidates in the disease area of endometriosis.
Cooperation with Janssen
In its collaboration with Janssen on a NR2B subtype selective
NMDA-antagonist portfolio for development against CNS diseases,
Evotec has reached an important validation milestone for a new
compound.
About Evotec AG
Evotec is a drug discovery alliance and development partnership
company focused on rapidly progressing innovative product
approaches with leading pharmaceutical and biotechnology companies.
We operate worldwide providing the highest quality stand-alone and
integrated drug discovery solutions, covering all activities from
target-to-clinic. The Company has established a unique position by
assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology, inflammation and infectious
diseases. Evotec has long-term discovery alliances with strategic
partners including Bayer, Boehringer Ingelheim, CHDI, Genentech,
Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In
addition, the Company has existing development partnerships and
product candidates both in clinical and pre-clinical development.
These include partnerships with Boehringer Ingelheim and MedImmune
in the field of diabetes, with Janssen Pharmaceuticals in the field
of depression and with Roche in the field of Alzheimer's disease.
For additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS — Information set
forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement
of Evotec as of the date of this press release. Such
forward-looking statements are neither promises nor guarantees, but
are subject to a variety of risks and uncertainties, many of which
are beyond our control, and which could cause actual results to
differ materially from those contemplated in these forward-looking
statements. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any such statements to
reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is
based.
CONTACT: For further information, please contact
Gabriele Hansen
VP, Corporate Communications & Investor Relations
+49.(0)40.560 81-255
+49.(0)40.560 81-333 Fax
gabriele.hansen@evotec.com
Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jul 2023 to Jul 2024